FDA Classifications: The Hidden Driver of AI Valuation

The regulatory path a clinical AI company takes is what sets its time-to-market, how much cash it burns through, and what the company is in the end worth. If you’re an early-stage healthcare VC or a regulatory compliance officer, you have to understand the details of FDA classifications because it’s a huge part of your diligence for predicting market entry speed and just figuring out if the company is viable. This is a quick breakdown of how FDA classifications like Software as a Medical Device (SaMD) versus Clinical Decision Support (CDS) tools really affect a startup’s capital, and it offers a way to think about pricing that regulatory risk right into a company’s valuation.

The Regulatory Chasm: SaMD vs. Clinical Decision Support

The first thing you have to get straight is the difference between SaMD and Clinical Decision Support (CDS), because that single distinction determines the regulatory headache and the investment needed to get a health AI tool to market. Software as a Medical Device (SaMD) is basically any software that’s meant for a medical purpose but isn’t physically attached to a hardware device. This classification puts it directly under the FDA’s thumb, meaning it needs premarket authorization, usually either a 510(k) Clearance or, if it’s a totally new kind of tool, a De Novo Classification. That regulatory process is a grind, sure, but once you’re through it, you have a perception of clinical validation that builds trust with doctors and, more importantly, with payers, which is what lets you command premium pricing and actually get reimbursed. A lot of AI companies try to live in the gray zone of Clinical Decision Support, though. The logic is that if the AI tool just gives information or spits out recommendations for a doctor who still makes the final decision, it might get to sidestep active FDA regulation. It’s a tempting, faster, and cheaper way to get to market, but it’s a major trade-off. Without that explicit FDA stamp of approval, convincing hospitals to buy in and payers to reimburse is a much harder fight. Hospital systems and payers almost always want to see that clear regulatory backing. For them, it’s a basic way to de-risk a new technology. A CDS classification might get a product launched quickly, but it can absolutely kill your chances of getting wide adoption from payers and will definitely put a cap on your exit multiples. So is the company being clever or just setting itself up for a dead end? As an investor, you have to get in there and figure out if their chosen classification actually matches up with a realistic commercial strategy.

Accelerating Market Entry: 510(k) vs. De Novo Timelines

The FDA premarket pathway you pick is what really dictates your time-to-market, and for an early-stage company, that’s almost entirely about how fast you burn through your cash. For most AI-native companies, the 510(k) Clearance path is the most direct way in, requiring you to prove that your new device is substantially equivalent to a “predicate” device that’s already on the market, which is all laid out in the FDA 510(k) pathway guidance. Some companies, like Viz.ai and Aidoc, have turned this into an art form. Viz.ai, for instance, has gotten 9 separate FDA AI clearances for its stroke detection algorithms by building on its previous submissions. Aidoc has done something very similar but on a larger scale, racking up 31 FDA 510(k) clearances for its tools that triage and flag critical findings in medical images. A solid, well-put-together 510(k) submission can get a clearance in 3 to 9 months, even though the FDA’s internal goal is just 90 days for a review. The De Novo Classification pathway is a different animal. This one is for new, low-to-moderate-risk devices that are so novel they don’t have an existing predicate to compare to. While it’s the only option for genuinely new AI, it’s also a much longer and more expensive process, with the FDA’s stated goal of a 150-day review often stretching out to 9 months or even longer. That kind of delay just incinerates cash and pushes out any hope of revenue. For an investor, a startup’s grasp of these timelines is a big deal. A company that gets stuck in a long regulatory cycle can easily become a “zombie company,” forced to raise round after round of funding just to stay alive while waiting for the FDA. A team that can lay out a clear, efficient regulatory plan, one that leans on the 510(k) process wherever possible, is a team that actually understands capital deployment.

Case Studies in Regulatory Strategy: Viz.ai, Aidoc, and Cleerly

You can learn a lot by looking at the regulatory histories of the big AI players and seeing how their choices affected their market traction and valuation. Viz.ai has been a real leader in acute care AI, and their strategy of securing 9 FDA AI clearances for their stroke platform by incrementally expanding their cleared indications shows a masterful understanding of the 510(k) process. They can iterate fast. Each one of those successful clearances makes their clinical case stronger and opens more doors with payers, which all feeds back into their high valuation. Their ability to predicate new features on existing clearances lets them keep a fast regulatory rhythm. Aidoc, another huge name in imaging AI, has followed a similar playbook, and they’ve now got 31 FDA 510(k) clearances for their radiology triage tools. This serial approach has allowed them to build out a whole portfolio of regulated SaMD products, which shows both technical capability and regulatory smarts. Those multiple clearances establish them as an authority and make them a very safe-looking bet. Cleerly is a different kind of story. They’re focused on quantitative coronary plaque analysis from CT scans, and their tech does something that wasn’t really possible with non-invasive cardiac tools before. Because it’s so new, their regulatory path is more complex and has likely involved De Novo submissions for diagnostic claims without direct predicates. That means they probably faced a longer initial wait to get to market, but the potential payoff is creating a “data moat” around a completely new clinical standard. Once a product like that is cleared, it can create huge market differentiation and, eventually, a much higher long-term valuation. An investor in Cleerly is making a bet on the massive future value of a unique, clinically-validated diagnostic that could one day get a very large reimbursement code.

Audience Takeaway: Red Flags in Regulatory Roadmaps

For VCs and compliance officers looking at early-stage health AI, you need to be skeptical when you review a company’s regulatory roadmap. Here are a few red flags that should make you dig in with more questions:

• Vague Regulatory Strategy: If the team is fuzzy on whether their product is SaMD or CDS, or if they’re going the 510(k) route but can’t name their target predicate devices, it means they have an immature plan that will cause delays. They need a defined plan.
• Over-reliance on Unregulated CDS Claims: A company trying to sell a diagnostic tool while claiming it’s just “unregulated CDS” is a huge red flag. Good luck getting paid for that. The line between Clinical Decision Support and actual Diagnostic AI is something the FDA guidance on CDS is very clear about.
• Unrealistic Timelines for De Novo Submissions: When a company pitches a De Novo pathway but gives you a timeline that sounds like a 510(k), they don’t understand the process and are seriously under-budgeting the capital they’ll need. A De Novo is a massive project.
• Absence of a Predetermined Change Control Plan (PCCP) for Adaptive AI: If it’s an AI/ML-driven SaMD that’s supposed to learn and change over time, the lack of a PCCP in their regulatory strategy is a deal-breaker. Without a plan approved by the FDA, every single model update could require a brand new 510(k) submission, which is an unscalable and incredibly expensive cycle. The FDA PCCP framework for AI/ML devices is the document you need to know.
• Lack of QMS / ISO 13485 Certification: You can’t even think about a serious regulatory submission without a strong Quality Management System (QMS) that’s compliant with standards like ISO 13485. If it’s missing, the company lacks basic operational maturity.

A company’s regulatory plan isn’t some checkbox. It’s a core strategic choice that dictates its cash burn, market timing, clinical standing, and final valuation. Investors who make a point of digging into regulatory risk as a driver of valuation are going to be the ones who find the best AI healthcare deals.

Methodology and Source Note

I pulled the information for this analysis from public sources, including the FDA’s own database, company regulatory announcements I’ve tracked, and general industry reporting. The timelines for De Novo and 510(k) pathways are based on what the FDA itself publishes and what we’ve all seen happen in practice. I verified the specific clearance numbers for Viz.ai and Aidoc by looking them up in the FDA’s 510(k) database.